Gene Therapy Lyfgenia denied as non-formulary by State Medicaid (varies)?

State Medicaid (varies)'s specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why State Medicaid Programs Issue Non-Formulary Denials for Lyfgenia

A non-formulary denial means Lyfgenia is not listed on the state Medicaid program's preferred drug list (PDL) or the managed care plan's formulary, so coverage requires an exception. Gene therapies are a new category of treatment, and many Medicaid formularies — built around recurring prescriptions — have not yet established defined pathways for one-time curative gene therapies. The absence from the formulary reflects an administrative lag, not a clinical judgment that the therapy is inappropriate.

Federal Medicaid law imposes an important limit on non-formulary denials: for individuals under age 21, the Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) mandate generally requires that any medically necessary service be covered even if it is not on the formulary. For adult Medicaid enrollees, a formulary exception process must be available.

## Why This Denial Is Appealable

Medicaid programs may not use formulary restrictions as a blanket barrier to medically necessary, FDA-approved treatments. The formulary exception process exists precisely for this situation. When a prescriber documents that the non-formulary drug is medically necessary and that formulary alternatives are inadequate or inappropriate, the exception must be evaluated on clinical grounds — not denied reflexively.

## Your Appeal Rights and Timeline

• Formulary exception request: Submit a formulary exception simultaneously with or before the formal appeal. Most states require a decision within a defined timeframe.
• State Medicaid fair hearing: File a hearing request within the deadline on the denial notice to preserve your rights while the exception is pending.
• EPSDT pathway (under 21): If the patient is under 21, explicitly invoke the EPSDT mandate in both the exception request and the appeal. This is a stronger legal basis than the formulary exception alone.
• Expedited process: Available for urgent medical situations — request it if the patient's condition warrants.

## Documentation to Gather

1. Diagnosis and indication confirmation: Records confirming the specific sickle cell disease genotype matching the FDA-approved indication. 2. Formulary alternative assessment: A prescriber statement reviewing each formulary alternative for sickle cell disease and explaining why each is inadequate, contraindicated, or has already failed for this patient. 3. Medical-necessity letter: The hematologist's letter establishing that Lyfgenia is medically necessary for this specific patient, addressing the clinical reasons that formulary alternatives are insufficient. 4. EPSDT documentation (if applicable): For patients under 21, a statement invoking EPSDT and confirming the service is medically necessary for correction of a covered condition. 5. FDA label: Attach the prescribing information confirming FDA approval and the approved indication.

## Criteria-Mapping Structure

Obtain the state's formulary exception criteria or medical-necessity exception policy. Address each requirement:

| Exception Criterion | Evidence Provided | |---|---| | Drug is FDA approved | Prescribing label attached | | Formulary alternatives tried or contraindicated | Prescriber letter with alternative-by-alternative analysis | | Medical necessity established | Hematologist letter + diagnosis + disease severity documentation | | EPSDT eligibility (if under 21) | Age confirmation + medical necessity statement |

State the EPSDT basis clearly if applicable — it shifts the legal burden meaningfully in favor of coverage.